← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	1,888	+11	+0.6%	$147B
2	2 Amgen AMGN $238B	1,367	+22	+2%	$93.7B
3	3 Eli Lilly LLY $1.13T	1,139	+21	+2%	$70.6B
4	4 McKesson MCK $116B	954	+28	+3%	$44.8B
5	5 Becton Dickinson BDX $52.4B	917	-15	-2%	$24.9B
6	6 Teva Pharmaceutical Industries Limited TEVA $48.2B	819	-3	-0.4%	$30.6B
7	7 Conagra Brands CAG $6.84B	657	+19	+3%	$14.2B
8	8 Regeneron Pharmaceuticals REGN $82.9B	541	+32	+6%	$37.7B
9	9 Novo Nordisk NVO $174B	517	+11	+2%	$11.3B
10	10 DaVita DVA $11.9B	497	+12	+2%	$14.4B
11	11 AstraZeneca AZN $260B	376	-10	-3%	$6.27B
12	12 ResMed RMD $33.9B	313	-13	-4%	$4.21B
13	13 Accendra Health ACH $22M	239	+6	+3%	$2.14B
14	14 Opko Health OPK $1.19B	219	+28	+15%	$1.38B
15	15 West Pharmaceutical WST $26.9B	219	+5	+2%	$3.93B
16	16 Herbalife HLF $1.52B	212	+10	+5%	$5.39B
17	17 Dr. Reddy's Laboratories RDY $10.8B	190	+16	+9%	$1.4B
18	18 MannKind Corp MNKD $1.01B	188	+4	+2%	$640M
19	19 Tootsie Roll Industries TR $2.92B	163	+2	+1%	$441M
20	20 Alaunos Therapeutics TCRT $5.34M	156	+28	+22%	$795M
21	21 DELISTED CATALENT, INC. CTLT	149	+31	+26%	$3.53B
22	22 Fresenius Medical Care FMS $11.8B	144	+4	+3%	$483M
23	ARNA 23 DELISTED Arena Pharmaceuticals Inc ARNA	130	+8	+7%	$649M
24	24 Medifast MED $136M	129	+2	+2%	$332M
25	25 DELISTED WW International WW	115	-18	-14%	$262M